PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

@article{Wood2000PTK787ZK2A,
  title={PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.},
  author={Jonathan Wood and Guido Bold and E Buchdunger and Robert Cozens and Stefano Ferrari and Joerg Frei and Francesco Hofmann and Juergen Mestan and Helmut Mett and Terence O'reilly and Elke Persohn and Johannes Dr. R{\"o}sel and Christian Schnell and David Stover and Andreas Theuer and Harry Towbin and Fritz Wenger and Kathie Woods-Cook and Andreas Menrad and Gerhard Siemeister and Michael Schirner and Karl Heinz Dr Thierauch and Marlon R Schneider and Joachim Drevs and Georg Martiny-Baron and Frank Totzke},
  journal={Cancer research},
  year={2000},
  volume={60 8},
  pages={
          2178-89
        }
}
PTK787/ZK 222584 (1-[4-chloroanilino]-4-[4-pyridylmethyl] phthalazine succinate) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, active in the submicromolar range. It also inhibits other class III kinases, such as the platelet-derived growth factor (PDGF) receptor beta tyrosine kinase, c-Kit, and c-Fms, but at higher concentrations. It is not active against kinases from other receptor families, such as epidermal growth factor receptor, fibroblast… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 291 CITATIONS, ESTIMATED 55% COVERAGE

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.

  • The Journal of pharmacology and experimental therapeutics
  • 2002
VIEW 15 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery.

  • Cytometry. Part A : the journal of the International Society for Analytical Cytology
  • 2009
VIEW 8 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

1992
2019

CITATION STATISTICS

  • 37 Highly Influenced Citations

  • Averaged 7 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 73 REFERENCES

Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2000
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Blockade of VEGF signalling is sufficient to completely prevent retinal neovascularization

H. Ozaki, M. S. Seo, +6 authors A CampochiaroP.
  • Am. J. Pathol.,
  • 2000
VIEW 2 EXCERPTS

New anilino-phthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor driven angiogenesis

G. Bold, Altmann, +26 authors J. M. Wood
  • J. Med. Chem., in press,
  • 2000
VIEW 1 EXCERPT